• $7.6m cash on balance sheet to fund multiple growth initiatives throughout FY26
• Upgraded Guidance to $28.0m revenue in FY25 and delivered $29.3m revenue, due solely to expansion in AUS market
• Certificate of GMP compliance with Europe, Canada, Singapore & UK allowing export to these markets

Bioxyne Limited (BXN.ASX) has released an updated investor presentation highlighting its strong Q4 FY25 performance and growth outlook. The company recorded record quarterly revenue of $9.5 million, representing a 204% increase on Q4 FY24 and a 33% increase on Q3 FY25. This growth was driven solely by the expansion of Bioxyne's Australian medical cannabis operations, including new contract wins and existing clients moving their manufacturing to Bioxyne. The company has $7.6 million in cash on its balance sheet to fund multiple growth initiatives throughout FY26. Bioxyne has also secured Certificates of GMP compliance with Europe, Canada, Singapore and the UK, allowing it to export its products to these key international markets. The company expects to see significant growth potential in its home Australian market, where it plans to double its market share in key product lines in FY26. Bioxyne also highlighted its strategic entries into the European and UK markets, with a €3.2 million (A$5.8 million) supply agreement with a German client and A$7 million exclusive agreement with NectarTek Australia. The company is doubling its GMP flower packing capacity to 30 tonnes as it targets 25% of the Australian medicinal cannabis flower market in FY26.

Bioxyne delivered $29.3 million in revenue for FY25, exceeding its guidance of $28 million by 4.6%. The company expects to provide FY26 guidance at the release of its FY25 results next month.

Bioxyne plans to continue accelerating its controlled drugs and GMP manufacturing accreditation in Czechia to serve EU markets, as well as progress its controlled drugs and GMP manufacturing accreditation in the UK. The company will also invest in inventory to meet significant international and Australian demand, and continue expanding supply opportunities for MDMA and Psilocybin. Substantial growth is anticipated in FY26 with multiple growth drivers underpinning revenue and margin expansion.